These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

256 related articles for article (PubMed ID: 31940630)

  • 21. SDF-1α/MicroRNA-134 Axis Regulates Nonfunctioning Pituitary Neuroendocrine Tumor Growth
    Wang X; Fang Y; Zhou Y; Guo X; Xu K; Li C; Zhang J; Hong Y
    Front Endocrinol (Lausanne); 2020; 11():566761. PubMed ID: 33362712
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effect of combined treatment with a pan-PI3K inhibitor or an isoform-specific PI3K inhibitor and everolimus on cell proliferation in GH-secreting pituitary tumour in an experimental setting.
    Pivonello C; Patalano R; Solari D; Auriemma RS; Frio F; Vitulli F; Grasso LFS; Di Cera M; De Martino MC; Cavallo LM; Cappabianca P; Colao A; Pivonello R
    Endocrine; 2018 Dec; 62(3):663-680. PubMed ID: 30066286
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Anticancer efficacy of simvastatin on prostate cancer cells and tumor xenografts is associated with inhibition of Akt and reduced prostate-specific antigen expression.
    Kochuparambil ST; Al-Husein B; Goc A; Soliman S; Somanath PR
    J Pharmacol Exp Ther; 2011 Feb; 336(2):496-505. PubMed ID: 21059805
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Multilineage Pituitary Neuroendocrine Tumors (PitNETs) Expressing PIT1 and SF1.
    Asa SL; Mete O; Riddle ND; Perry A
    Endocr Pathol; 2023 Sep; 34(3):273-278. PubMed ID: 37268858
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Molecular determinants of the response to medical treatment of growth hormone secreting pituitary neuroendocrine tumors.
    Fuentes-Fayos AC; García-Martínez A; Herrera-Martínez AD; Jiménez-Vacas JM; Vázquez-Borrego MC; Castaño JP; Picó A; Gahete MD; Luque RM
    Minerva Endocrinol; 2019 Jun; 44(2):109-128. PubMed ID: 30650942
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Inhibition of Barret's adenocarcinoma cell growth by simvastatin: involvement of COX-2 and apoptosis-related proteins.
    Konturek PC; Burnat G; Hahn EG
    J Physiol Pharmacol; 2007 Aug; 58 Suppl 3():141-8. PubMed ID: 17901590
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The potential use of simvastatin for cancer treatment: A review.
    Duarte JA; de Barros ALB; Leite EA
    Biomed Pharmacother; 2021 Sep; 141():111858. PubMed ID: 34323700
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Somatostatin analogues: treatment of pituitary and neuroendocrine tumors.
    Colao A; Faggiano A; Pivonello R
    Prog Brain Res; 2010; 182():281-94. PubMed ID: 20541670
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Examination of the direct effects of metabolic factors on somatotrope function in a non-human primate model, Papio anubis.
    Luque RM; Gahete MD; Valentine RJ; Kineman RD
    J Mol Endocrinol; 2006 Aug; 37(1):25-38. PubMed ID: 16901921
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The effect of statins in colorectal cancer is mediated through the bone morphogenetic protein pathway.
    Kodach LL; Bleuming SA; Peppelenbosch MP; Hommes DW; van den Brink GR; Hardwick JC
    Gastroenterology; 2007 Oct; 133(4):1272-81. PubMed ID: 17919499
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Simvastatin exhibits antiproliferative effects on spheres derived from canine mammary carcinoma cells.
    Torres CG; Olivares A; Stoore C
    Oncol Rep; 2015 May; 33(5):2235-44. PubMed ID: 25778435
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Differential expression levels of β-catenin are associated with invasive behavior of both functional and non-functional pituitary neuroendocrine tumor (PitNET).
    Taghavi SF; Ghorbani M; Panahi M; Nazem S; Karimi M; Salimi V; Tavakoli-Yaraki M
    Mol Biol Rep; 2023 Aug; 50(8):6425-6434. PubMed ID: 37326745
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Octreotide and pasireotide (dis)similarly inhibit pituitary tumor cells in vitro.
    Ibáñez-Costa A; Rivero-Cortés E; Vázquez-Borrego MC; Gahete MD; Jiménez-Reina L; Venegas-Moreno E; de la Riva A; Arráez MÁ; González-Molero I; Schmid HA; Maraver-Selfa S; Gavilán-Villarejo I; García-Arnés JA; Japón MA; Soto-Moreno A; Gálvez MA; Luque RM; Castaño JP
    J Endocrinol; 2016 Nov; 231(2):135-145. PubMed ID: 27587848
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Direct effects of catecholamines, thyrotropin-releasing hormone, and somatostatin on growth hormone and prolactin secretion from adenomatous and nonadenomatous human pituitary cells in culture.
    Ishibashi M; Yamaji T
    J Clin Invest; 1984 Jan; 73(1):66-78. PubMed ID: 6140273
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Simvastatin and atorvastatin as inhibitors of proliferation and inducers of apoptosis in human cholangiocarcinoma cells.
    Buranrat B; Senggunprai L; Prawan A; Kukongviriyapan V
    Life Sci; 2016 May; 153():41-9. PubMed ID: 27098189
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Immune Landscape of Pituitary Tumors Reveals Association Between Macrophages and Gonadotroph Tumor Invasion.
    Principe M; Chanal M; Ilie MD; Ziverec A; Vasiljevic A; Jouanneau E; Hennino A; Raverot G; Bertolino P
    J Clin Endocrinol Metab; 2020 Nov; 105(11):. PubMed ID: 32785693
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Inhibitory effects of SOM230 on adrenocorticotropic hormone production and corticotroph tumor cell proliferation in vitro and in vivo.
    Murasawa S; Kageyama K; Sugiyama A; Ishigame N; Niioka K; Suda T; Daimon M
    Mol Cell Endocrinol; 2014 Aug; 394(1-2):37-46. PubMed ID: 25011056
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Simvastatin Up-Regulates Annexin A10 That Can Inhibit the Proliferation, Migration, and Invasion in Androgen-Independent Human Prostate Cancer Cells.
    Miyazawa Y; Sekine Y; Kato H; Furuya Y; Koike H; Suzuki K
    Prostate; 2017 Mar; 77(4):337-349. PubMed ID: 27862098
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Lower
    Tjörnstrand A; Casar-Borota O; Heurling K; Schöll M; Gjertsson P; Himmelman J; Itsenko O; Ragnarsson O; Filipsson Nyström H
    Clin Endocrinol (Oxf); 2020 Mar; 92(3):222-231. PubMed ID: 31868239
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Impact of gsp oncogene on the mRNA content for somatostatin and dopamine receptors in human somatotropinomas.
    Taboada GF; Neto LV; Luque RM; Córdoba-Chacón J; de Oliveira Machado E; de Carvalho DP; Kineman RD; Gadelha MR
    Neuroendocrinology; 2011; 93(1):40-7. PubMed ID: 21079388
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.